OBJECTIVES: To estimate efficacy, safety and adherence to therapy of ankylosing spondlitis (AS) patients included in the Czech National Registry ATTRA, and to look for predictive factors for therapy discontinuation. METHODS: Patients were included according to the guidelines of the Czech Society for Rheumatology, which involve failure of previous therapy, BASDAI >4, and CRP >10 mg/l. Only patients with anti-TNF administered for the first time were analysed. Adherence to therapy was evaluated using Kaplan-Meier analysis and results were presented as cumulative survival. Comparison with data on patients with rheumatoid arthritis (RA) followed in the same registry was made. RESULTS: 310 of AS patients who had reached at least 1 year as well as those who discontinued the treatment before this time point were analysed. Drug survival was longer in patients with AS than in those with RA: 84% vs. 78% and 72% vs. 49% after 1 and 3 years of treatment. Significant risk factors for treatment discontinuation were female gender (RR 2.22, p=0.001) and CRP (RR 1.33, p=0.025). The proportion of patients with BASDAI <4 during the treatment period was higher in the etanercept group than in the infliximab group (p<0.001). The number of patients fully employed increased in the whole group from 48% to 63% after 1 year of treatment. CONCLUSION: Follow-up of patients with AS in the national registry shows that it is an effective and safe way of treatment with longer adherence to anti-TNF therapy in comparison with RA patients.
OBJECTIVES: To estimate efficacy, safety and adherence to therapy of ankylosing spondlitis (AS) patients included in the Czech National Registry ATTRA, and to look for predictive factors for therapy discontinuation. METHODS:Patients were included according to the guidelines of the Czech Society for Rheumatology, which involve failure of previous therapy, BASDAI >4, and CRP >10 mg/l. Only patients with anti-TNF administered for the first time were analysed. Adherence to therapy was evaluated using Kaplan-Meier analysis and results were presented as cumulative survival. Comparison with data on patients with rheumatoid arthritis (RA) followed in the same registry was made. RESULTS: 310 of AS patients who had reached at least 1 year as well as those who discontinued the treatment before this time point were analysed. Drug survival was longer in patients with AS than in those with RA: 84% vs. 78% and 72% vs. 49% after 1 and 3 years of treatment. Significant risk factors for treatment discontinuation were female gender (RR 2.22, p=0.001) and CRP (RR 1.33, p=0.025). The proportion of patients with BASDAI <4 during the treatment period was higher in the etanercept group than in the infliximab group (p<0.001). The number of patients fully employed increased in the whole group from 48% to 63% after 1 year of treatment. CONCLUSION: Follow-up of patients with AS in the national registry shows that it is an effective and safe way of treatment with longer adherence to anti-TNF therapy in comparison with RApatients.
Authors: Márta Péntek; Gyula Poór; Piotr Wiland; Martina Olejárová; Marek Brzosko; Catalin Codreanu; Nóra Brodszky; László Gulácsi Journal: Eur J Health Econ Date: 2014-05-16
Authors: Bárbara P Fafá; Paulo Louzada-Junior; David C Titton; Eliana Zandonade; Roberto Ranza; Ieda Laurindo; Paula Peçanha; Aline Ranzolin; André L Hayata; Angela Duarte; Inês G Silveira; Izaias Costa; José C Macieira; Luiz S Guedes-Barbosa; Manoel B Bertolo; Maria Fátima Lobato da C Sauma; Marília B G Silva; Marlene Freire; Morton A Scheinberg; Vander Fernandes; Washington Bianchi; José R S Miranda; Geraldo R C Pinheiro; Hellen M S Carvalho; Claiton Viegas Brenol; Ivanio A Pereira; Gláucio Ricardo Werner de Castro; Júlio C Bertacini de Morais; Sheila K F Oliveira; Mirhelen Mendes de Abreu; Roberto A Toledo; Marcelo M Pinheiro; Walber Pinto Vieira; Valéria Valim Journal: Clin Rheumatol Date: 2015-04-08 Impact factor: 2.980
Authors: Lisa Lindner; Anja Weiß; Andreas Reich; Siegfried Kindler; Frank Behrens; Jürgen Braun; Joachim Listing; Georg Schett; Joachim Sieper; Anja Strangfeld; Anne C Regierer Journal: Arthritis Res Ther Date: 2021-07-07 Impact factor: 5.156